• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 16th June 2021

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?

Our new paper explores the evidence currently being used to allocate budgets between public sector activities in the UK and its limitations. We argue that there is much that can and should be done to improve the evidence base to…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Our new paper explores the evidence currently being used to allocate budgets between public sector activities in the UK and its limitations. We argue that there is much that can and should be done to improve the evidence base to inform the allocation of public sector budgets across portfolios. We propose a pragmatic approach to measure and value disparate public sector outputs in a commensurate manner.

Our new paper, Allocating public spending efficiently: is there a need for a better mechanism to inform decisions in the UK and elsewhere? explores the evidence currently being used to allocate budgets between public sector activities in the UK and its limitations. We argue that there is much that can – and should – be done to improve the evidence base to inform the allocation of public sector budgets across portfolios. We propose a pragmatic approach to measure and value disparate public sector outputs in a commensurate manner.

One of the remarkable achievements of health economics as a sub-discipline of economics has been the widespread international use of evidence on the cost effectiveness of new technologies in the health care sector, via Health Technology Appraisal. The considerable efforts made to ensure that new technologies are effective and good value for money – explicitly recognising the opportunity cost of these decisions – helps to ensure health care budgets are used in ways that maximise benefits to patients and society from the health service budget.

These efforts stand in stark contrast to the way in which the total budgets for health care are decided, and how taxpayer spending is allocated between the health care sector and other areas of public sector activity.  In the UK (as in many other countries around the world), few – if any – formal processes explicitly address comparisons of value for money between spending across different government departments, despite the existence of mechanisms that could – in principle – achieve that. This leaves a very important gap in evidence and means that decisions about public spending allocations are likely to miss opportunities to improve the health and wellbeing of society from existing budgets.

In our new paper, we argue that the development of methods and evidence to better inform the allocation of public sector spending between departments is urgently needed. We identify a number of possible approaches to this – some of which are being used in different countries – and highlight their strengths and weaknesses.

We propose a new, pragmatic approach that incorporates a generic descriptive system to measure the disparate outcomes produced by public sector activities in a commensurate manner. Discrete choice experiments could be used to generate evidence of the relative importance placed on these different aspects of public sector outcomes by members of the general public. The proposed approach could be used to produce evidence on the relative effectiveness of different public sector activities in improving outcomes, and evidence on the relative value of these outcomes that would facilitate comparisons of value for money across government departments.  An advantage of adopting such an approach is its ability to go beyond a sector-specific focus to evaluate options that generate disparate outcomes spanning multiple sectors, the importance of which has been amply demonstrated by COVID-19 and measures to contain the pandemic.

The lack of progress toward improving the evidence base for public sector spending is worrying, given how much is at stake in these decisions. Greater public good could potentially be achieved from existing budgets just by reallocating those budgets toward those public sector activities with higher value to society.  We recognise that government budget allocation decisions will correctly remain a political decision, which will necessarily reflect a variety of considerations and judgements that will go beyond even the broad set of outcomes that would form the basis of our proposed approach: even when developed fully, it would be a decision aid to inform and illuminate a complex process. However, we would contend that the efficiency of public spending could be significantly improved, and the transparency of political choices improved by the availability of a comparative evidence base.

Acknowledgement: Part of this work was funded by the Association of British Pharmaceutical Industry as a research grant.

Citation

Cubi-Molla, P., Buxton, M. & Devlin, N. Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere? Applied Health Economics & Health Policy (2021). https://doi.org/10.1007/s40258-021-00648-2.

  • Health Technology Assessment…
  • Measuring and Valuing Outcomes
  • ABPI

Related Insights

Cancer_WellcomeCollection_landscape
  • Insight
  • January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Read more
G7Antibiotics_blog_featuredimage
  • Insight
  • December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

Read more
Slide3
  • Insight
  • October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Read more
HealthData&Stats_AdobeStock_168196575_landscape
  • Insight
  • August 2022

Improving the Measurement of Valued Output in Primary Care in England

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!